Rapid XR-BUP induction without SL-BUP stabilization was safe and associated with significant OD rate reductions in a shelter-based harm reduction setting.
Rapid XR-BUP induction without SL-BUP stabilization was safe and associated with significant OD rate reductions in a shelter-based harm reduction setting.
These findings suggest that reported increases in ASD occurrence estimates from service-based surveillance may be influenced by detection-related factors.
Tavapadon (Juvmo, AbbVie) is the first and only selective D1/D5 dopamine receptor agonist for adults with Parkinson’s disease, marking the first new dopaminergic treatment approach for the PD in decades. Approval was based on the Phase 3 TEMPO clinical trial program, which demonstrated significant improvements in motor symptoms, daily functioning, and increased “on” time without troublesome dyskinesia in patients with Parkinson’s disease.
The AAPP membership has elected three members to serve on the 2027-2029 Board of Directors. Assuming their positions effective July 1, 2027, will be Drs. Michael McGuire, Sarah Thomason and Kara Wong.
No summary available
No summary available
No summary available
On Sept. 8, the DOL's Employee Benefits Security Administration (EBSA) published new interim guidelines for enforcing treatment limitations under the original 2008 Mental Health Parity and Addiction Equity Act. The Trump administration has signaled intent to create a new proposed rule entirely, but this interim guideline aims to clarify enforcement of the nonquantitative treatment limitation (NQTL) requirements in the meantime.
On Thursday, September 17, 2026, the Joint Commission of Pharmacy Practitioners (JCPP) convened leaders of national pharmacy organizations in Alexandria, Virginia, to explore healthcare megatrends shaping the future of pharmacy practice. AAPP was represented by AAPP President Suzie Harris and Executive Director Brenda Schimenti.
PCSS-MOUD added a supplemental course to its SUD 101 Core Curriculum: Managing Common Psychiatric Conditions in Patients with Substance Use Disorders, presented by Ellen L. Edens, MD. Check out this on-demand educational activity!
Psychedelic therapy and the current and future roles for psychiatric pharmacists in the USA
US drug overdose deaths involving stimulants without opioids continued to rise in 2024
Care Navigation for Methamphetamine Use Disorder-A Randomized Clinical Trial
Impact of Addiction Consult Service on Alcohol Use Disorder Medications and Postdischarge Outcomes
This is your chance to get involved with the important work being done by AAPP committees and editorial boards. Through October 28, AAPP will be accepting applications for volunteer openings anticipated for the 2027-2028 committee year which starts March/April. Selections will be made and announced no later than January 2027. Apply today!
This is your chance to get involved with the important work being done by AAPP committees and editorial boards. Through October 28, AAPP will be accepting applications for volunteer openings anticipated for the 2027-2028 committee year which starts March/April. Selections will be made and announced no later than January 2027. Apply today!
AAPP submitted comments on CMS's CY 2027 Medicare Physician Fee Schedule proposed rule, supporting policies that strengthen integrated behavioral healthcare and expand access to psychiatric medication expertise. The letter endorses increased payment for the Psychiatric Collaborative Care Model (CoCM), supports permanent telehealth flexibilities, and encourages CMS to recognize psychiatric pharmacists as Medicare providers as it advances primary care payment reform.
Evaluating Large Language Models in Response to Questions on Substance Use: Helpful or Harmful?
Understanding Recovery Capital and Transitions Out of Recovery Homes: Socio-Demographic Factors and Reported Reasons for Departure
Rethinking Punitive Responses to Underage Marijuana Use in the Era of Legalization: Insights from an Online Survey
People Seeking Treatment for Meth/Amphetamine Use Are Getting Older and Treatment Services Need to Adapt
Oral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial
Learn how psychiatric pharmacists impact suicide prevention.
AAPP submitted comments supporting the DEA’s proposal to temporarily place concentrated 7-hydroxymitragynine (7-OH) products in Schedule I due to growing concerns about their opioid-like effects, including dependence, withdrawal, overdose, and other serious health risks. AAPP noted that these highly concentrated products are increasingly available online and in retail settings with limited oversight and often contain much higher levels of 7-OH than occur naturally in kratom.
This paper will discuss intrinsic and extrinsic motivators of treatment, as well as patient nonadherence and disengagement from services, including the effects of perceived coercion, insight, and the therapeutic alliance.